|
AU2003282877B9
(en)
*
|
2002-09-25 |
2011-05-12 |
University Of Massachusetts |
In Vivo gene silencing by chemically modified and stable siRNA
|
|
HRP20171969T1
(hr)
|
2008-10-15 |
2018-04-06 |
Ionis Pharmaceuticals, Inc. |
Modulacija ekspresije faktora 11
|
|
SG10201809460SA
(en)
|
2008-10-20 |
2018-11-29 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expression of transthyretin
|
|
WO2012053741A2
(ko)
|
2010-10-22 |
2012-04-26 |
성균관대학교산학협력단 |
Rna 간섭을 유도하는 핵산 분자 및 그 용도
|
|
WO2012068405A2
(en)
|
2010-11-17 |
2012-05-24 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
SG194751A1
(en)
|
2011-06-30 |
2013-12-30 |
Arrowhead Res Corp |
Compositions and methods for inhibiting gene expression of hepatitis b virus
|
|
US10023861B2
(en)
|
2011-08-29 |
2018-07-17 |
Ionis Pharmaceuticals, Inc. |
Oligomer-conjugate complexes and their use
|
|
HK1200191A1
(en)
|
2011-11-18 |
2015-07-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
WO2013075035A1
(en)
|
2011-11-18 |
2013-05-23 |
Alnylam Pharmaceuticals |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
|
WO2013173789A2
(en)
|
2012-05-17 |
2013-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
|
US10125362B2
(en)
|
2012-05-22 |
2018-11-13 |
Olix Pharmaceuticals, Inc. |
RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
|
|
DK3354734T3
(da)
|
2012-06-21 |
2020-06-29 |
Miragen Therapeutics Inc |
Oligonukleotid-baserede hæmmere omfattende låst nukleinsyremønster
|
|
JP2015525797A
(ja)
*
|
2012-08-06 |
2015-09-07 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
糖質コンジュゲートrna剤およびその調製方法
|
|
US9879041B2
(en)
|
2012-11-28 |
2018-01-30 |
Victoria Link Limited |
Saccharide dendritic cluster compounds as inhibitors of BACE-1
|
|
PE20152002A1
(es)
*
|
2013-05-01 |
2016-01-21 |
Isis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de ttr y vhb
|
|
SG11201508925WA
(en)
*
|
2013-05-01 |
2015-11-27 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
WO2014205451A2
(en)
|
2013-06-21 |
2014-12-24 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
AU2014360314B2
(en)
|
2013-12-06 |
2018-04-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
|
|
IL314045A
(en)
*
|
2013-12-12 |
2024-09-01 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
JP6482475B2
(ja)
*
|
2014-01-07 |
2019-03-13 |
レナセラピューティクス株式会社 |
アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
|
|
EP3119888B1
(en)
|
2014-03-19 |
2021-07-28 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating ataxin 2 expression
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
SI3757214T1
(sl)
|
2014-04-01 |
2022-08-31 |
Biogen Ma Inc. |
Sestave za moduliranje izražanja SOD-1
|
|
EP3647318B1
(en)
|
2014-04-28 |
2021-06-30 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
|
EP3137115B1
(en)
|
2014-05-01 |
2020-10-14 |
Ionis Pharmaceuticals, Inc. |
Method for synthesis of reactive conjugate clusters
|
|
ES2812099T3
(es)
*
|
2014-05-01 |
2021-03-16 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
|
|
ES2844593T3
(es)
|
2014-05-01 |
2021-07-22 |
Ionis Pharmaceuticals Inc |
Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
|
|
RS59182B1
(sr)
|
2014-05-01 |
2019-10-31 |
Ionis Pharmaceuticals Inc |
Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
US10436802B2
(en)
|
2014-09-12 |
2019-10-08 |
Biogen Ma Inc. |
Methods for treating spinal muscular atrophy
|
|
CA2964979A1
(en)
|
2014-11-14 |
2016-05-19 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for the modulation of proteins
|
|
EP4242329A3
(en)
|
2014-12-08 |
2023-10-25 |
Berg LLC |
Use of markers including filamin a in the diagnosis and treatment of prostate cancer
|
|
EP4372091A3
(en)
|
2014-12-12 |
2024-07-31 |
Tod M. Woolf |
Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
US9885042B2
(en)
|
2015-01-20 |
2018-02-06 |
MiRagen Therapeutics, Inc. |
miR-92 inhibitors and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
US10487103B2
(en)
|
2015-03-24 |
2019-11-26 |
Gifu University |
Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them
|
|
WO2016161429A1
(en)
|
2015-04-03 |
2016-10-06 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating tmprss6 expression
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
MY192997A
(en)
|
2015-07-10 |
2022-09-20 |
Ionis Pharmaceuticals Inc |
Modulators of diacyglycerol acyltransferase 2 (dgat2)
|
|
US20180193471A1
(en)
*
|
2015-07-16 |
2018-07-12 |
Kyowa Hakko Kirin Co., Ltd. |
ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE
|
|
PL3329002T3
(pl)
|
2015-07-31 |
2021-04-19 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
|
|
WO2017027350A2
(en)
|
2015-08-07 |
2017-02-16 |
Arrowhead Pharmaceuticals, Inc. |
Rnai therapy for hepatitis b virus infection
|
|
EP3334499A4
(en)
|
2015-08-14 |
2019-04-17 |
University of Massachusetts |
BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
|
|
SG10201913209WA
(en)
|
2015-09-24 |
2020-02-27 |
Ionis Pharmaceuticals Inc |
Modulators of kras expression
|
|
US10533175B2
(en)
|
2015-09-25 |
2020-01-14 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Ataxin 3 expression
|
|
JP2018530325A
(ja)
|
2015-10-08 |
2018-10-18 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
アンジオテンシノーゲンの発現を調節するための化合物及び方法
|
|
HRP20241087T1
(hr)
|
2015-11-06 |
2024-11-08 |
Ionis Pharmaceuticals, Inc. |
Konjugirani protusmisleni spojevi za upotrebu u terapiji
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
CN108699556B
(zh)
|
2015-11-16 |
2023-02-17 |
奥利克斯医药有限公司 |
使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
WO2017117496A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
AU2017205462A1
(en)
|
2016-01-05 |
2018-06-07 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing LRRK2 expression
|
|
CA3022874A1
(en)
|
2016-02-02 |
2017-08-10 |
Olix Pharmaceuticals, Inc. |
Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1
|
|
CN108779464B
(zh)
|
2016-02-02 |
2022-05-17 |
奥利克斯医药有限公司 |
使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
|
|
MX2018009854A
(es)
|
2016-03-07 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos dirigidos para compuestos terapeuticos.
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
US10961271B2
(en)
|
2016-03-16 |
2021-03-30 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
CN109072238B
(zh)
|
2016-04-11 |
2022-05-24 |
奥利克斯医药有限公司 |
使用靶向结缔组织生长因子的rna复合物治疗特发性肺纤维化
|
|
EP4023228A1
(en)
|
2016-05-06 |
2022-07-06 |
Tod M. Woolf |
Genome editing oligonucleotide without programmable nucleases
|
|
FI3469073T3
(fi)
|
2016-06-09 |
2024-04-17 |
Centre Nat Rech Scient |
Kemiallisesti modifioidun kapsidin omaava raav
|
|
CA3023514A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
|
IL264216B2
(en)
|
2016-07-15 |
2024-04-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulation of smn2
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
WO2018031933A2
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
CN116832169A
(zh)
|
2016-09-02 |
2023-10-03 |
箭头药业股份有限公司 |
靶向配体
|
|
KR20190065341A
(ko)
|
2016-10-06 |
2019-06-11 |
아이오니스 파마수티컬즈, 인코포레이티드 |
올리고머 화합물들의 접합 방법
|
|
WO2018085752A2
(en)
*
|
2016-11-07 |
2018-05-11 |
nanoSUR LLC |
Post-transcriptionally chemically modified double strand rnas
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
WO2018146557A2
(en)
|
2017-02-10 |
2018-08-16 |
Dong Ki Lee |
Long double-stranded rna for rna interference
|
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
|
EP3603648B1
(en)
|
2017-03-29 |
2025-09-17 |
Shionogi & Co., Ltd |
Complex of nucleic acid medicine and multibranched lipid
|
|
RS63836B1
(sr)
|
2017-04-05 |
2023-01-31 |
Silence Therapeutics Gmbh |
Proizvodi i sastavi
|
|
WO2018223056A1
(en)
|
2017-06-02 |
2018-12-06 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
US11597927B2
(en)
*
|
2017-06-02 |
2023-03-07 |
Wave Life Sciences Ltd. |
Oligonucleotide compositions and methods of use thereof
|
|
EP3668984A4
(en)
|
2017-08-18 |
2021-09-08 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATH FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
|
WO2019051173A1
(en)
|
2017-09-08 |
2019-03-14 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF SMAD7 EXPRESSION
|
|
BR112020005230A2
(pt)
|
2017-09-19 |
2020-09-24 |
Alnylam Pharmaceuticals, Inc. |
composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
|
|
SG11202002940QA
(en)
|
2017-11-01 |
2020-04-29 |
Alnylam Pharmaceuticals Inc |
Complement component c3 irna compositions and methods of use thereof
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
KR20250107294A
(ko)
|
2017-12-01 |
2025-07-11 |
쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 |
핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
|
|
JP7273417B2
(ja)
|
2017-12-01 |
2023-05-15 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
WO2019105418A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
|
|
WO2019105419A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
EP3728281A1
(en)
*
|
2017-12-21 |
2020-10-28 |
Alnylam Pharmaceuticals Inc. |
Chirally-enriched double-stranded rna agents
|
|
DK3732185T3
(da)
|
2017-12-29 |
2025-03-31 |
Suzhou Ribo Life Science Co Ltd |
Konjugater og fremstilling og anvendelse heraf
|
|
MX2020007369A
(es)
|
2018-01-15 |
2020-10-28 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de dnm2.
|
|
AU2019218987B2
(en)
|
2018-02-12 |
2025-04-24 |
Ionis Pharmaceuticals, Inc. |
Modified compounds and uses thereof
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
CN111511915A
(zh)
|
2018-03-09 |
2020-08-07 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
|
PE20201349A1
(es)
|
2018-04-11 |
2020-11-30 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de ezh2
|
|
BR112020020670A2
(pt)
|
2018-04-12 |
2021-03-02 |
Wave Life Sciences Ltd. |
composição de oligonucleotídeo, composição farmacêutica, método para alterar o splicing de uma transcrição alvo, método para tratar distrofia muscular, método para preparar um oligonucleotídeo ou uma composição de oligonucleotídeo do mesmo e oligonucleotídeo
|
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
|
JP7279081B2
(ja)
|
2018-05-08 |
2023-05-22 |
レグルス セラピューティクス インコーポレイテッド |
Mir-122を調節するためのマイクロrna化合物及び方法
|
|
WO2019217708A1
(en)
|
2018-05-09 |
2019-11-14 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn3 expression
|
|
SG11202010012PA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing fxi expression
|
|
TWI844541B
(zh)
|
2018-05-11 |
2024-06-11 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組成物及其使用方法
|
|
AU2019287635B2
(en)
|
2018-06-14 |
2026-02-12 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020018558A1
(en)
|
2018-07-17 |
2020-01-23 |
Aronora, Inc. |
Methods for safely reducing thrombopoietin
|
|
CA3106986A1
(en)
|
2018-07-25 |
2020-01-30 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn2 expression
|
|
US20210292768A1
(en)
|
2018-08-08 |
2021-09-23 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
|
AU2019316640B2
(en)
|
2018-08-10 |
2026-03-12 |
University Of Massachusetts |
Modified oligonucleotides targeting SNPs
|
|
EP3842534A4
(en)
|
2018-08-21 |
2022-07-06 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
|
|
EP3840759A4
(en)
|
2018-08-23 |
2022-06-01 |
University Of Massachusetts |
O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES
|
|
TWI869213B
(zh)
|
2018-09-19 |
2025-01-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
|
CA3109553A1
(en)
|
2018-09-19 |
2020-03-26 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use
|
|
WO2020063198A1
(zh)
|
2018-09-30 |
2020-04-02 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
AU2019380940A1
(en)
|
2018-11-15 |
2021-06-03 |
Ionis Pharmaceuticals, Inc. |
Modulators of IRF5 expression
|
|
EP3884053A4
(en)
|
2018-11-21 |
2023-02-01 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION
|
|
SG11202106378VA
(en)
|
2018-12-21 |
2021-07-29 |
Ionis Pharmaceuticals Inc |
Modulators of hsd17b13 expression
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
AU2020207935A1
(en)
*
|
2019-01-18 |
2021-08-26 |
University Of Massachusetts |
Dynamic pharmacokinetic-modifying anchors
|
|
TW202214854A
(zh)
|
2019-01-31 |
2022-04-16 |
美商Ionis製藥公司 |
Yap1表現之調節劑
|
|
MX2021010152A
(es)
|
2019-02-27 |
2021-09-14 |
Ionis Pharmaceuticals Inc |
Moduladores de la expresion de malat1.
|
|
MD3947684T2
(ro)
|
2019-03-29 |
2025-10-31 |
Ionis Pharmaceuticals Inc |
Compuși și metode pentru modularea UBE3A-ATS
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
CA3139195A1
(en)
|
2019-05-22 |
2020-11-26 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
EP3974530A4
(en)
|
2019-05-22 |
2023-07-12 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD OF MANUFACTURE AND USE
|
|
JP7610849B2
(ja)
|
2019-05-24 |
2025-01-09 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
EP4660307A2
(en)
|
2019-07-26 |
2025-12-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
JP7692829B2
(ja)
|
2019-07-30 |
2025-06-16 |
塩野義製薬株式会社 |
Murf1を標的とする核酸医薬
|
|
KR20220061972A
(ko)
|
2019-09-10 |
2022-05-13 |
다이이찌 산쿄 가부시키가이샤 |
간장 송달용 GalNAc-올리고뉴클레오티드 콘주게이트 및 제조 방법
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
JP7757277B2
(ja)
|
2019-10-14 |
2025-10-21 |
アストラゼネカ・アクチエボラーグ |
Pnpla3発現のモジュレーター
|
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
EP4076434A1
(en)
|
2019-12-17 |
2022-10-26 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
CN120505310A
(zh)
|
2020-02-28 |
2025-08-19 |
Ionis制药公司 |
用于调节smn2的化合物和方法
|
|
CA3172591A1
(en)
|
2020-03-24 |
2021-09-30 |
Douglas Anthony KERR |
Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
|
|
IL296660A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
|
JP2023522957A
(ja)
|
2020-04-21 |
2023-06-01 |
フラッグシップ パイオニアリング, インコーポレイテッド |
二機能性分子およびその使用方法
|
|
IL297435A
(en)
|
2020-05-01 |
2022-12-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating atxn1
|
|
US12534724B2
(en)
|
2020-05-26 |
2026-01-27 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
JP7799640B2
(ja)
|
2020-06-29 |
2026-01-15 |
アイオーニス ファーマシューティカルズ, インコーポレーテッド |
Plp1を調節するための化合物及び方法
|
|
US12384814B2
(en)
|
2020-07-28 |
2025-08-12 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing app expression
|
|
PE20231567A1
(es)
|
2020-08-07 |
2023-10-04 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular el scn2a
|
|
MX2023005736A
(es)
|
2020-11-18 |
2023-05-25 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular la expresion de angiotensinogeno.
|
|
CR20230308A
(es)
|
2020-12-11 |
2023-09-08 |
Civi Biopharma Inc |
Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
|
|
CA3205040A1
(en)
|
2020-12-18 |
2022-06-23 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating factor xii
|
|
JP2024500878A
(ja)
|
2020-12-21 |
2024-01-10 |
フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド |
組織再生を増加させるための細胞代謝回転因子の使用
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
US20230390411A1
(en)
*
|
2021-01-28 |
2023-12-07 |
Nanjing Chempion Biotechnology Co., Ltd. |
Conjugate and use thereof
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
EP4320440A1
(en)
|
2021-04-06 |
2024-02-14 |
BPGbio, Inc. |
Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
|
|
US20230059578A1
(en)
|
2021-04-06 |
2023-02-23 |
Berg Llc |
Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
|
|
IL307528A
(en)
|
2021-04-06 |
2023-12-01 |
Bpgbio Inc |
Protein markers for the prognosis of breast cancer progression
|
|
AU2022264509A1
(en)
|
2021-04-27 |
2023-12-14 |
Generation Bio Co. |
Non-viral dna vectors expressing therapeutic antibodies and uses thereof
|
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
|
KR20240023602A
(ko)
|
2021-06-18 |
2024-02-22 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ifnar1 발현을 감소시키기 위한 화합물 및 방법
|
|
IL309334A
(en)
|
2021-06-23 |
2024-02-01 |
Univ Massachusetts |
Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
|
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
CN115920065A
(zh)
*
|
2021-08-02 |
2023-04-07 |
南方科技大学 |
一种可靶向去唾液酸糖蛋白受体的配体及其缀合物与用途
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
IL311518A
(en)
|
2021-10-01 |
2024-05-01 |
Adarx Pharmaceuticals Inc |
Preparations that modulate perkalkerine and methods of using them
|
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
CA3237769A1
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Gata4-targeted therapeutics for treatment of cardiac hypertrophy
|
|
WO2023086295A2
(en)
|
2021-11-10 |
2023-05-19 |
University Of Rochester |
Antisense oligonucleotides for modifying protein expression
|
|
CN117756866A
(zh)
*
|
2022-01-30 |
2024-03-26 |
大睿生物医药科技(上海)有限公司 |
含有n-乙酰半乳糖胺的靶向配体
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
US11879125B2
(en)
|
2022-03-16 |
2024-01-23 |
Empirico Inc. |
GalNAc compositions for improving siRNA bioavailability
|
|
AU2023245603A1
(en)
|
2022-03-28 |
2024-11-07 |
Empirico Inc. |
Modified oligonucleotides
|
|
CN117264950A
(zh)
*
|
2022-07-07 |
2023-12-22 |
北京福元医药股份有限公司 |
用于抑制c5基因表达的双链核糖核酸及其修饰物、缀合物和用途
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
EP4581143A1
(en)
|
2022-08-29 |
2025-07-09 |
University of Rochester |
Antisense oligonucleotide-based anti-fibrotic therapeutics
|
|
US12152052B2
(en)
|
2022-09-23 |
2024-11-26 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing MECP2 expression
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
EP4669749A1
(en)
|
2023-02-21 |
2025-12-31 |
Vib Vzw |
OLIGONUCLEOTIDES TO MODULATE SYNAPTOGYRIN-3 EXPRESSION
|
|
WO2024175586A2
(en)
|
2023-02-21 |
2024-08-29 |
Vib Vzw |
Inhibitors of synaptogyrin-3 expression
|
|
EP4698652A2
(en)
|
2023-04-20 |
2026-02-25 |
Adarx Pharmaceuticals, Inc. |
Mapt-modulating compositions and methods of use thereof
|
|
KR20260021635A
(ko)
|
2023-05-12 |
2026-02-13 |
아다르엑스 파마슈티컬스, 인크. |
Nmda 리간드 접합 화합물 및 이의 용도
|
|
CN121335980A
(zh)
|
2023-05-26 |
2026-01-13 |
阿达尔克斯制药有限公司 |
Sod1调节组合物及其使用方法
|
|
TW202506137A
(zh)
|
2023-06-20 |
2025-02-16 |
美商雅迪克斯製藥公司 |
Lrrk2調節組合物及其使用方法
|
|
GB202314724D0
(en)
|
2023-09-26 |
2023-11-08 |
Astrazeneca Ab |
compounds and methods for reducing psd3 expression
|
|
US12553050B2
(en)
|
2024-03-22 |
2026-02-17 |
Takeda Pharmaceutical Company Limited |
Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
|
|
WO2026044153A1
(en)
|
2024-08-21 |
2026-02-26 |
Bpgbio, Inc. |
Use of biomarkers in the diagnosis of pancreatic cancer
|
|
WO2026041784A1
(en)
|
2024-08-23 |
2026-02-26 |
Vib Vzw |
Oligonucleotides for modulating synaptogyrin-3 expression
|